Will OXFORD BIODYNAMICS stock go up?

According to Danelfin AI, OXFORD BIODYNAMICS has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (37.60%) is -12.09% vs. the average probability (49.69%) of all European stocks.

Is it a good time to buy, sell, or hold OXFORD BIODYNAMICS stock right now?

OXFORD BIODYNAMICS has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (37.60%) is -12.09% vs. the average probability (49.69%) of all European stocks, based on our AI-powered analysis. You can find more details on whether OXFORD BIODYNAMICS stock is a good buy .

What is going on with OXFORD BIODYNAMICS stock in the last 3 months?

The OXFORD BIODYNAMICS stock performance in the last quarter has been -.

Does OXFORD BIODYNAMICS offer dividend payments?

No, OXFORD BIODYNAMICS does not currently pay dividends.

What is the current market capitalization of OXFORD BIODYNAMICS?

OXFORD BIODYNAMICS's market cap is GBX 4.29M, as of 2026-07-02 08:00.

Oxford Biodynamics PLC (OBD.L) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

OBD.L AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score

Strong Sell

OXFORD BIODYNAMICS (OBD.L) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -12.09% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.69%) and the probability of OBD.L (37.60%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.69%
OBD.L probability advantage of beating the market (3M)-12.09%
OBD.L probability of beating the market (3M)37.60%

OBD.L probability advantage of beating the market (3M): -12.09%

The AI-powered overall analysis of OXFORD BIODYNAMICS (OBD.L) is based on the 0 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of OBD.L:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
-	-	-	-	-

OBD.L probability advantage of beating the market (3M)Total:-12.09%
OBD.L AI Score

Significant changes Vs previous day

OBD.L Trading Parameters

Trading parameters are unavailable for OBD.L.

OBD.L Frequently Asked Questions

Will OXFORD BIODYNAMICS stock go up?
According to Danelfin AI, OXFORD BIODYNAMICS has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (37.60%) is -12.09% vs. the average probability (49.69%) of all European stocks.
Is it a good time to buy, sell, or hold OXFORD BIODYNAMICS stock right now?
What is going on with OXFORD BIODYNAMICS stock in the last 3 months?
Does OXFORD BIODYNAMICS offer dividend payments?
What is the current market capitalization of OXFORD BIODYNAMICS?

Oxford Biodynamics PLC Company Profile

OXFORD BIODYNAMICS PLC (OBD.L) is a biotechnology company that develops and commercializes precision medicine solutions. It focuses on diagnostic tests and services for the healthcare and pharmaceutical industries. The company utilizes its proprietary technology to analyze epigenetic biomarkers. This analysis supports early disease detection, prognosis, and personalized treatment strategies. Its offerings aim to improve patient outcomes and streamline drug development processes.

The company's core offering is the EpiSwitch™ platform, which represents a novel approach to biomarker discovery. This platform analyzes 3D genomic architecture to identify unique biomarker signatures. It provides deep insights into disease mechanisms, progression, and individual patient responses to therapies. The EpiSwitch™ technology enables the development of highly specific and sensitive diagnostic tools. These tools assist clinicians and researchers in making more informed decisions regarding patient care and therapeutic interventions.

OXFORD BIODYNAMICS PLC develops various diagnostic tests based on its platform for different medical needs. One such test is EpiSwitch™ Prostate Screening (EPS), a blood-based test that aids in the early detection and risk stratification of prostate cancer. This test offers a non-invasive method for assessing prostate cancer risk. The company also offers EpiSwitch™ CiRT, a diagnostic test designed to predict patient response to checkpoint inhibitor therapies in oncology. These diagnostic products support personalized treatment approaches by providing crucial information for therapeutic selection.

Beyond diagnostics, the company applies its EpiSwitch™ platform in drug discovery and development programs. It collaborates with pharmaceutical partners to identify novel drug targets and validate therapeutic candidates. The platform also helps in patient stratification for clinical trials, ensuring more targeted and efficient drug evaluation. This capability assists in developing companion diagnostics, which are essential for guiding therapeutic selection and monitoring treatment efficacy throughout a patient's journey. The technology provides valuable data for optimizing drug pipelines.

The company serves a diverse client base, including pharmaceutical companies, contract research organizations, and healthcare providers. It distributes its products and services through a combination of direct sales efforts and strategic partnerships with diagnostic laboratories and research institutions. OXFORD BIODYNAMICS PLC generates revenue from product sales, service fees for research collaborations, and licensing agreements, reaching customers globally.

Sector:
Country:United Kingdom
Industry:
Address:3140 Rowan Place, John Smith Drive, Oxford Business Park South, OXFORD
Employees:41
Website:oxfordbiodynamics.com

Pros

Proprietary 3D genomics biomarker discovery platform

High switching costs for integrated drug development partners

Scalability of platform across multiple disease indications

Potential for recurring revenue from diagnostic test licensing

Regulatory approval creating market entry barriers

Cons

Substantial capital intensity for ongoing research and development

Pros

Cons

Company

AI Score

Compare

ECX.FEpigenomics AG

DXRX.LDiaceutics PLC

ALERS.PAEurobio Scientific SA

SBTX.LSkinBioTherapeutics PLC

EXPRS2.STExpreS2ion Biotech Holding AB

Company

AI Score

Compare

OBD.L Top 10 Industry Stocks

Life Sciences Tools & Services

	Company	AI Score	Compare
1	PANG.MCPangaea Oncology SA
2	SFZN.SWSiegfried Holding AG
3	DXRX.LDiaceutics PLC
4	ERF.PAEurofins Scientific SE
5	DIM.PASartorius Stedim Biotech SA
6	BANB.SWBachem Holding AG
7	MLC.IRMalin Corporation PLC
8	CHEMM.COChemometec A/S
9	GUBRA.COGubra A/S
10	HEN.WA

	Company	AI Score	Compare

OBD.L Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	REC.MIRecordati Industria Chimica e Farmaceutica SpA
2	FAE.MCFaes Farma SA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS
6	LAB.MCLabiana Health SA
7	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
8	MPARK.E.ISMLP Saglik Hizmetleri AS
9	PRM.MCPrim SA
10	AEVS.SWAevis Victoria SA

	Company	AI Score	Compare

OBD.L Stock AI Analysis High Risk